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Urgently seeking efficiency and sustainability of clinical trials 
in global health
Jay J H Park, Rebecca F Grais, Monica Taljaard, Etheldreda Nakimuli-Mpungu, Fyezah Jehan, Jean B Nachega, Nathan Ford, Denis Xavier, 
Andre P Kengne, Per Ashorn, Maria Eugenia Socias, Zulfiqar A Bhutta, Edward J Mills
This paper shows the scale of global health research and the context in which we frame the subsequent papers in the 
Series. In this Series paper, we provide a historical perspective on clinical trial research by revisiting the 1948 
streptomycin trial for pulmonary tuberculosis, which was the first documented randomised clinical trial in the 
English language, and we discuss its close connection with global health. We describe the current state of clinical trial 
research globally by providing an overview of clinical trials that have been registered in the WHO International 
Clinical Trial Registry since 2010. We discuss challenges with current trial planning and designs that are often used in 
clinical trial research undertaken in low-income and middle-income countries, as an overview of the global health 
trials landscape. Finally, we discuss the importance of collaborative work in global health research towards generating 
sustainable and culturally appropriate research environments.
Introduction
The field of global health prioritises improving health 
and achieving health equity for all. Research in this area 
is focused on improving health outcomes and addressing 
inequities in low-income and middle-income countries 
(LMICs).1,2 LMICs continue to have comparatively higher 
rates of and burden from infectious diseases and other 
communicable diseases (eg, HIV, malaria, diarrhoeal 
diseases, and sepsis) than do high-income countries 
(HICs). Among many health challenges, shorter life 
expectancy and higher rates of maternal and child 
mortality in LMICs, relative to HICs, have delayed their 
developmental and economic potential.3–5 Thus, inter-
ventions to reduce disease and improve health in LMICs, 
particularly, should be a global priority.
Progress has been made in the prevention and 
treatment of infectious diseases and other com-
municable diseases, with randomised clinical trials 
(RCTs) having been used to generate evidence on the 
effectiveness of important therapeutics. RCTs are 
considered robust methods for evaluating the 
effectiveness of therapies because these studies fulfil the 
primary assumption of statistical testing—ie, the 
equality of treatment by minimising selection bias and 
creating groups that are comparable in prognostic 
factors—thereby establishing a causal effect of the 
treatment on the outcome.6,7 RCTs are an important 
methodological tool in global health research for 
generating high-level evidence to inform the 
development of context-specific and international 
guidelines on preferred interventions that can be 
delivered at scale to populations in need.5 
Although the challenges in reducing the burden of 
communicable diseases in LMICs are considerable, 
there have been important demographic and epidemio-
logical shifts occurring rapidly in LMICs. The global 
population is estimated to increase from approximately 
7·7 billion people in 2019, to 8·5 billion by 2030, and 
further to 9·7 billion people in 2050.6 The most rapid 
growth is projected to occur in sub-Saharan Africa, with 
the population size expected to double by 2050.6 With the 
increasing life expectancy in LMICs, there will be a 
consequent increase in the burden of non-communicable 
diseases (NCDs), because these diseases are more 
common in adults older than 65 years.7–9 This rapid 
change in population size and demographics, in addition 
to the rising burden of NCDs, presents many challenges 
for meeting the Sustainable Development Goals.8–10 
A change in approach is needed to rapidly answer 
research questions that can accompany the changes 
in demographics and disease burden in LMICs, where 
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Key messages
• Low-income and middle-income countries face the most 
rapidly occurring demographic and epidemiological 
transitions globally that threaten sustainable global 
development.
• Clinical trial research has an inherent connection with 
global health research that aims to answer important 
questions for populations in need, but there is a mismatch 
in clinical trial efforts and disease burden globally. Of the 
324 854 randomised clinical trials that have been 
registered from 2010 to 2019, our analysis has shown that 
only 17 777 (5%) of the trials were set in south Asia and 
only 5756 (2%) of the trials were set in sub-Saharan 
African countries.
• Clinical trials that are undertaken in low-income and 
middle-income countries can be improved by promoting 
new methodological innovations that can be leveraged to 
improve the ability of the local regions across low-income 
and middle-income countries to sustain research 
infrastructure and human resources for long-term gains.
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resources are limited and health research capacity is 
low. In the current era, efficient research designs 
that can answer multiple complex research questions 
simultaneously with a minimised sample size and trial 
duration will be beneficial, but there are also many 
logistical and methodological barriers to overcome 
before such an approach is a reality.
This paper in the Series reviews the close connection 
of global health with methodological research. We 
summarise the current landscape of global health trial 
research, the limits of conventional approaches to trials, 
and challenges in trial planning.
History of RCTs
Global health research is inherently connected to clinical 
trials. Sir Austin Bradford Hill advocated for RCTs for at 
least a decade before the first peer-reviewed RCT in the 
English language was published in 1948.11–13 According 
to Bradford Hill, the concept of randomisation was 
extraneous to the individuals of the medical community 
in the UK, many of whom rejected the notion at the 
time.13
The 1948 streptomycin trial for pulmonary 
tuberculosis from the UK Medical Research Council11 
changed the landscape of medicine and public health. 
The trial was done shortly after World War 2, a time of 
immense resource limitations and widespread illness 
and injuries.13 The war had effectively stripped the UK 
of financial resources and the government could only 
afford to purchase streptomycin, a new drug for treating 
tuberculosis, for only 55 patients.13,14 Economic hardship 
was a dominant reason that made this RCT possible. 
The high burden of tuberculosis and scarce drug 
resources justified the UK Medical Research Council 
in using an RCT, to ensure the fair distribution of 
a scarce drug supply and to obtain a reliable answer 
regarding the effectiveness of streptomycin for treating 
tuberculosis.11,13,15
In the seven decades since, the pharmaceutical industry, 
particularly in the area of oncology research, has made 
several important advancements in statistical analysis, 
simulation methods, and outcome assessments for 
innovative designs, such as adaptive trial designs and 
master protocols.16–19 These innovative designs have 
also been used, although scarcely, in specialised fields, 
such as clinical neonatology.19,20 However, uptake of these 
methods has been poor in global health research,21,22 much 
like the situation in which the medical community was 
initially reluctant to embrace the concept of randomisation 
less than a century ago. With the increasing challenge of 
the double burden of NCDs and communicable diseases 
in the context of global health, questions to be answered 
are manifold and more complex; however, human 
resources and research infrastructure in LMICs are 
limited. Adopting methodological innovations to clinical 
trial design and implementation has the potential to bring 
the efficiency needed to global health research.
Current landscape of trial research in global 
health
Although any definition of global health is contentious, in 
this Series, we will refer to global health research as any 
clinical research undertaken in a collaboration between 
researchers in HICs and LMICs, in which most intended 
monetary funding comes from outside of the country that 
the research is conducted in. This definition recognises 
the potential power imbalance among researchers and 
among sponsoring institutions. Throughout this Series, 
we discuss several limitations of current, possibly 
inefficient and often outdated, approaches to trial design, 
but it is important to note that these criticisms apply 
equally to all those working in global health research, 
including (or potentially predominantly) researchers in 
HICs designing these studies and the funders sponsoring 
them, in light of these power imbalances.
Mismatch between research efforts and disease burden
There is a well recognised mismatch between research 
efforts (eg, number of clinical trials) and disease 
burden.23 Despite public health efforts to minimise 
disparities in health, research efforts have largely been 
focused towards the interests of HICs (eg, the USA 
and the UK), particularly in markets for which high 
commercial interests and sustained public funding 
exist. Several studies have shown that most clinical 
trial research is undertaken in HICs.23–26 According to 
the WHO International Clinical Trial Registry, as of 
Nov 5, 2019, RCTs in LMIC settings have only accounted 
for 109 713 (32%) of 342 854 RCTs registered worldwide 
(figure 1). Despite 24% (1·8 billion people estimated for 
2019) of the global population currently residing in 
south Asia, this region is the setting of only 5% (n=17 777) 
of all RCTs worldwide.6 Sub-Saharan African countries 
(which had a population of 1·1 billion people in 2019) 
are the setting of an even smaller proportion of RCTs, at 
2% (n=5756).6
The low number of RCTs represents a missed 
opportunity for LMICs and suggests the need for more 
clinical trial research in global health. When global health 
clinical trials are undertaken, they are often done with 
insufficient funding to support sustained development of 
research infrastructure and human resources in the 
LMICs in which they are set. To maintain clinical trial 
research efforts in global health over the long term, the 
ability to sustain research infrastructure and human 
resources for local settings through consolidated and 
minimised single-use research activities related to trial 
planning and execution is crucial.
Efforts to support local ownership and coproduction 
of health research in LMICs are rare.27 In key topical 
fields of global health research, such as HIV and AIDS, 
malaria, and tuberculosis, there is a low first-authorship 
of researchers from LMICs on publications, raising a 
concern of rare opportunities for research, career advance-
ment, and capacity building for LMIC researchers.28
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Importance of location and context
The world is often dichotomised into the industrialised 
world versus the developing world. In global health 
research, there are often tendencies to ignore the 
different contextual factors between different LMICs and 
to search for common interventions that will improve 
health across multiple countries in many diverse 
populations.29 However, the reality is that there is often 
no one-size-fits-all solution because there is substantial 
heterogeneity between and within different countries.30
Different biological and socioeconomic factors of the 
trial location should be considered during the planning 
stage, to determine whether the research question is 
being asked in the right setting. For instance, despite a 
total of 168 460 neonates having been studied across 
12 trials in LMICs, a 2017 Cochrane review by Haider 
and colleagues31 reported inconclusive evidence for 
neonatal vitamin A supplementation on infant mortality. 
There were conflicting findings between different 
individual studies that had importantly different rates of 
maternal vitamin A deficiency and infant mortality.31 It 
is ill-advised to undertake clinical trials on vitamin 
A supplements among populations with low or no 
vitamin A deficiency. If these resources had instead been 
allocated to undertaking trials in regions where the 
prevalence of vitamin A deficiency is high, it is likely that 
there would be more conclusive evidence to support or 
refute the benefits of vitamin A supplementation on 
infant mortality.
It is beneficial if biological samples are collected, 
to better understand the biological mechanisms of differ-
ent interventions. Biological information can become 
especially important when the statistical assessment of 
the clinical outcomes show no difference. Collection of 
biological samples allow for mechanistic analyses to be 
undertaken alongside the main analyses of clinical trials, 
to better understand what happens biologically when an 
intervention is given. If laboratory analyses can show no 
biological associations, negative trial results could mean 
that the intervention probably does not have the initial 
hypothesised effects.29
In addition to biological analyses, consideration of 
clinical events that occur after a given intervention is 
initiated (ie, intercurrent events) is important. Intercurrent 
events, such as discontinuation of intervention, switching 
intervention, and use of rescue medications, are often 
handled with simple intention-to-treat (ITT) analyses.32 
The ITT principle is intended to measure the effective-
ness of intervention in real-world conditions, in which 
participants will not adhere perfectly to the protocol.33,34 
Figure 1: Global overview of clinical trial research
(A) Percentage of registered randomised clinical trials worldwide. (B) Percentage 
of trials that are cluster-randomised, by country, from the WHO International 
Clinical Trials Registry Platform from Jan 1, 2010, to Nov 5, 2019. (C) Number of 
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However, the intercurrent events can increase the 
variability of the data and make interpreting the study 
findings difficult. For instance, with the ITT principle, the 
discontinuation of an intervention is often ignored in the 
main analysis even though this action will affect the 
clinical outcomes of the participants in the study. Given 
that ITT analysis is used as the main primary analysis, 
different analytical strategies to handle discontinuation of 
intervention or other intercurrent events as sensitivity 
analyses are beneficial to explore the robustness of the 
ITT analysis.33,35
Affinity towards conventional designs
In global health research, conventional fixed trial 
designs are most often used for clinical research. Fixed 
trial designs refer to a type of design in which the trial 
data are analysed only once, when the trials are finished, 
after determining a sample size a priori.36,37 Fixed trial 
designs do not plan for any modifications to major 
design com ponents (eg, sample size, allocation ratio, 
and number of interventions) throughout the trial.36–38 
In clinical trials, data are accumulated over time, and 
some clinical trials might take years to complete. Fixed 
trial designs do not permit learning during the trial 
from the accumulating trial interim data because the 
interim data are not analysed throughout the trial. 
Investigators usually make assumptions about the 
population, inter ventions, outcomes, and other trial 
parameters on the basis of information that is available 
at the planning stage, and continue these assumptions 
throughout the trial until the last participant has 
completed their follow-up.
It is difficult to determine why methodological 
advancements in clinical trials have been slow to develop 
or gain acceptance in global health research. Advocacy 
for clinical trial education in LMICs has predominantly 
occurred via academic medical journals. The leading 
journals have published widely on methodological issues 
advocated by expert groups, such as the Consolidated 
Standards of Reporting Trials, Grading of Recom-
mendations, Assessment, Development, and Evaluation, 
and Cochrane collaborations, which have historically 
placed a primacy on individual quality indicators of 
clinical trials. These quality indicators have examined 
issues that can affect the precision of trial estimates and 
their likelihood of introducing bias. However, scoring 
the quality of clinical trials can be misleading and 
potentially hazardous if clinical decisions or public 
health decisions are influenced by evidence that could 
later be contradicted.39 Many of the methodological 
features that are considered key to determining the 
quality of a trial, including blinding, reporting of ITT 
analysis, allocation concealment, and sequence genera-
tion, have clear benefits, but there are issues with these 
features when evaluating whether randomised trials with 
a different design should be considered in policy making; 
a more nuanced approach is needed, given that there 
have been inconsistent findings as to whether these 
features are actually important to biasing study results.40,41 
However, these features are still routinely taught and are 
embedded in WHO guideline evaluations to determine 
whether guidelines provide strong evidence or not. The 
global health community could benefit from gaining an 
understanding of more innovative methods that are now 
available.
In the past few decades, important methodological 
advancements, particularly in adaptive trial designs, 
have sought to offset limitations that conventional 
trial designs can pose.17,42 An adaptive trial design, an 
extension of conventional fixed trial designs, is a type of 
trial design that allows for prespecified modifications (or 
adaptations) to the trial design during the trial, including 
plans for interim evaluations and decision rules.16,17,37 
Adaptive trial designs do not necessarily impose modifi-
cations to a trial: if prespecified decision rules are not 
met according to the trial data, the trial would continue 
without any adaptations and function as if the trial 
had a fixed trial design (figure 2). In brief, an adaptive 
trial design is a data-driven approach to a clinical trial 
investigation that allows trial modifications before an a 
priori sample size target has been reached.
Common examples of adaptive trial designs include 
group sequential designs and sample size reassess-
ment.17,37,38 A group sequential design is a type of design 
that allows for early stopping with stopping rules, usually 
based on a frequentist statistical metric in test statistics 
(typically p value boundaries).17,43 If the interim data 
assessment shows crossing of stopping boundaries, then 
the trial might stop under a group sequential design. 
With more frequent observations, inflation of type I error 
rates can occur (multiplicity), especially without statistical 
adjustments. In a commonly used group sequential 
design, such as the O’Brien-Fleming approach, the 
stopping boundaries are set more stringently with more 
interim analyses to preserve a significance level for the 
final analysis that is close to the significance level of a 
single analysis (eg, 5% α).43 Sample size reassessment is 
another type of adaptive trial design that allows for an 
increase in sample size based on interim data.17,38 Sample 
size reassessment was developed to mitigate risks for 
false-negative findings.
Although adaptive trial designs have received substantial 
attention in recent years, they are not without limitations. 
Every clinical question deserves a thorough investigation 
and consideration of the pros and cons when selecting 
design options and there should be no default design 
choice. An efficient trial design for one research question 
can be inefficient for another. Undertaking smarter trials 
requires a thorough con sideration of multiple candidate 
designs during the planning stage, ideally with the use of 
statistical simulations to weigh the efficiencies of different 
designs. Further discussion of adaptive trial designs and 
case studies are provided in the second44 and fourth45 
papers of this Series.
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Inadequate planning practices
Often in global health research, very little information is 
available regarding epidemiology and infrastructure in the 
context of the investigation, which can make trial planning 
difficult. Sample size calculations are a key challenge 
due to the unfamiliarity with regard to local epidemiology 
and expected treatment effects or accepted minimally 
clinical important difference. The recommended process 
of determining a realistic or important target difference 
between treatments has previously been described in the 
difference elicitation in trials (also known as DELTA²) 
guidance.46
Sample size calculations are a simplistic form of 
simulating a trial, and sample size calculations for RCTs 
with dichotomous outcomes require prespecification of 
operating characteristics, event rates in the control and 
intervention groups (ie, desired or expected effect sizes), 
and the rate of loss to follow-up. In most research 
areas within global health, operating characteristics are 
usually selected by convention at 80% statistical power 
and 5% type I error rate. There are no conventions 
for selecting event and treatment effect parameters 
when investigating dichotomous or other outcomes 
(eg, continuous and count outcomes). Clinical trials are 
often underpowered even when the planned sample size 
is reached due to erroneous assumptions used for sample 
size calculations, such as lower incidence of events than 
planned and lower treatment effects than anticipated. At 
the other extreme, the trial could be overpowered and 
too many participants might be recruited into a given 
trial, wasting time and resources.38 Consequently, the 
development of essential guidance might be delayed 
because another trial is required, or because the original 
trial has taken longer than necessary.
Appropriate sample size calculations are dependent on 
correct assumptions of design parameters. Often in 
global health research, clinical trials are planned on the 
basis of nationally representative cross-sectional survey 
data, such as Demographic and Health Surveys and 
Multiple Indicator Cluster Surveys, which monitor and 
evaluate programme implementation at a national level.47 
Although these cross-sectional surveys are valuable for 
these purposes, their use for trial planning, including 
sample size calculations, can be limited. These surveys 
fail to show temporal variability that might exist in 
disease severity because these cross-sectional surveys 
are not undertaken annually; Demographic and Health 
Surveys are typically carried out every 5 years48 and 
Multiple Indicator Cluster Surveys are carried out every 
3 years.49 Additionally, these surveys report on the national 
or regional prevalence of disease, and not the incidence, 
and can miss important geographical or demographic 
heterogeneity.
Assumptions used for sample size calculations can 
also be based on findings from previous studies. The use 
of a thorough literature review is important to identify 
reliable estimates; however, making such assumptions 
by extrapolation from previous studies can also have 
limitations. Researchers must account for how similar 
(or dissimilar) a previous study is to the trial being 
planned, including the recency of the study findings, or 
geographical and demographic differences. Even when 
there are recently undertaken studies with geographical 
and demographic similarities, there are still possibilities 
of having unexpected findings (panel).
However, sample size calculations are only a small 
part of efficient trial planning. A thorough consideration 
of all accessible scientific knowledge and exploration 
of multiple scenarios to anticipate potential risks and a 
range of expected results is also required in the planning 
stage.37 This approach can be achieved by use of compu-
tational simulations of study results under various 
scenarios that test the fragility of assumptions and weigh 
the pros and cons of different candidate design strategies 
for smarter trial planning.53 Despite its importance, only a 
few examples of clinical trials incorporating simulations 
exist in global health research.54–56
Cluster trial designs
Cluster-randomised trials are a type of clinical trial 
that involve randomisation of groups or clusters of 
Figure 2: Conventional fixed trial designs and common adaptive trial designs
(A) A two-arm randomised clinical trial with conventional fixed trial design. 
(B) A two-arm trial with SSR. If the first interim analysis shows worse results 
than expected, an SSR can be carried out by use of the interim results. An SSR is 
not permitted in a traditional non-adaptive trial, so even when the original 
planned sample size is reached, the trial might be underpowered. If SSR is 
permitted, the sample size could be increased to ensure that the trial is 
adequately powered. (C) A two-arm trial with response adaptive 
randomisation. The  response adaptive randomisation design allows for 
preferential assignment of interventions that show favourable interim results. 
In this example, the response adaptive randomisation design allows for an 
increased allocation ratio to treatment 1 based on the interim results. 
SSR=sample size reassessment.
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participants, rather than individuals.57 Cluster trials are 
appropriate for settings in which the use of individual 
randomisation is not feasible due to the nature of 
interventions being evaluated or in which substantial 
contamination is unavoidable. Cluster trials might also be 
used in cases for which the final aim is to evaluate the 
effectiveness of interventions at a mean cluster level.57 
Therefore, such trials are useful for evaluating the 
effectiveness of interventions or practices at the population 
level. For instance, in the early 1990s, several cluster trials 
were undertaken to determine the effects of insecticide-
treated bednets for malaria prevention,58–62 because testing 
these bednets in patient-level RCTs would not have been 
feasible. These cluster trials have provided strong evidence 
for the effectiveness of insecticide-treated bednets, a core 
component of malaria prevention efforts in LMICs.63
Compared with HICs, cluster trials are more 
frequently undertaken in LMICs even though there are far 
fewer RCTs undertaken (figure 1). In HICs, cluster RCTs 
are undertaken relatively infrequently, with only 
1657 (0·72%) cluster trials of all 231 477 trials documented; 
by contrast, the proportion of cluster trials is more than 
doubled in south Asia (308 [1·73%] cluster trials of all 
17 777 trials) and eight times higher in sub-Saharan Africa 
(354 [6·04%] cluster trials of all 5859 trials). Although 
there are instances in which cluster trials are appropriate 
(eg, when interventions cannot be delivered at the 
individual level), it is important to note that cluster trials 
can be expensive to carry out due to their statistical 
inefficiencies. Because the observations of individuals 
within the same cluster are usually correlated, there 
are statistical inefficiencies associated with cluster 
randomisation. To achieve statistical control of the 
probability of false-negative risks and false-positive risks 
(eg, 80% statistical power and 5% type I error rate), cluster 
trials require a much larger number of participants than 
individually randomised trials. Detailed discussions of 
cluster trial designs in the context of global health are 
provided in the third paper64 of this Series.
Factorial trial designs
Factorial clinical trials are a type of clinical trial that 
simultaneously test the effect of two or more interventions 
with the use of various combinations of interventions.65 
For instance, in a two-by-two factorial trial design, 
participants or clusters are randomised to one of the four 
combinations of two interventions (eg, A and B); the 
combination of these intervention strategies (A alone, B 
alone, and A plus B combined) can be compared against a 
control arm that does not receive intervention A or B. 
Factorial trial designs can be appealing because two or 
more interventions can be assessed at the same time in the 
same population simultaneously.66 Assuming that there is 
no interaction between the interventions, factorial designs 
can be an efficient way to test multiple interventions. 
Factorial designs can also allow for the testing of treatment 
interactions, but, depending on treatment interaction 
effects, these designs can result in sample sizes often four 
times higher than a comparable two-arm trial.66 To 
undertake efficient factorial clinical trials, it is important to 
have a reliable estimate of the treatment interaction effects. 
Such estimations can be challenging because reliable 
estimates regarding treat ment interaction often do not 
exist. Treatment inter action estimates are essential for 
determining sample size requirements because inter-
actions can substantially increase the needed sample size. 
Implementing factorial trials can also be more operationally 
challenging than two-arm trials because such trials usually 
involve multiple arms.
Building on long-term research infrastructure 
and capacity in global health
There is a need to build long-term research infrastructure 
and capacity in LMICs for long-term sustainability.67,68 In 
the context of global health, limited infrastructure and 
capacity in some regions can pose a challenge in carrying 
out clinical research.69 However, it is important to 
recognise that some regions have not been given a long-
term opportunity to build and sustain an infrastructure 
Panel: A rural Tanzania-based cluster trial studying the efficacy of topical repellent on 
malaria transmission (ISRCTN92202008)
Between July, 2009, and August, 2010, a placebo-controlled cluster trial was undertaken 
in a rural village in Tanzania (Mbingu village of the Ulanga district) to evaluate the 
efficacy of topical repellent on reducing malaria transmission.50 After sample size 
calculation, it was determined that enrolling 10 clusters of 47 households (each with five 
family members) would yield 90% statistical power at a 5% type I error rate, assuming a 
30% control event rate of evening malaria transmission (primary outcome) and a 
treatment effect size of 80% risk reduction.50
Several assumptions were made to justify the 30% control event rate for sample size 
calculation, given that there were no available estimates of malaria transmission in this 
region.50 The trial investigators assumed a malaria incidence rate of 1·0 malaria case per 
person per year on the basis of available estimates of fever incidence rate among children 
younger than 5 years (3·2 cases per person per year51), under the assumptions that only a 
proportion of fevers are caused by malaria and that the village population would be less 
prone to fevers than children.50 Because it has been previously estimated that 30% of 
mosquito bites occur in early evenings,52 the trial investigators justified the control event 
rate of 30% by combining the assumed malaria incidence rate with the proportion of 
evening mosquito bites.50
During the trial, Tanzania had a drought that reduced the malaria transmission rate, which 
led to a lower control event rate, meaning that the trial became underpowered due to the 
drought. This trial did not identify any benefits of topical repellent in malaria transmission 
reduction. The investigators have attributed the negative effects to the lower malaria 
infection rate, because only a 6% infection rate was identified in the trial instead of the 
anticipated 30% infection rate.50 Despite the unexpected challenges that occurred, this trial 
continued until its intended completion date as originally planned, with 4426 individuals 
being enrolled.50 When observed control event rates are considerably lower than the rates 
anticipated for initial trial planning, clinical trials, in turn, will be underpowered and there 
will be little (or no) promise of providing conclusive answers. To anticipate for such 
instances, prespecifying mechanisms of applying a futility analysis through adaptive trial 
designs could be useful.
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that would also allow for local training and professional 
development to be improved. There is a need to grow a 
large network of competent research groups by 
dedicating long-term funding for infrastructure and 
professional development, while ensuring that LMIC 
investigator-initiated or institution-initiated trials that 
aim to provide answers to local priorities have precedence.
The adoption and application of data-driven 
methods (eg, adaptive trial designs) has been scarce in 
global health research,70–74 despite their potential to save 
resources, improve the chance of identifying effective 
interventions, and address certain ethical concerns. 
Additionally, long-term trials that test multiple inter-
ventions with the use of a common control under a 
master protocol framework—perhaps the most efficient 
of all trial designs—have mainly been done in HICs, and 
not in LMICs (figure 1).21,22 A master protocol refers to a 
framework in which clinical trial research is undertaken 
with an overarching design that has been developed to 
evaluate multiple hypotheses with the aims of improving 
efficiency and establishing uniformity through stan-
dardisation of procedures in the development and 
evaluation of interventions.18,75,76 Master protocols can 
differentiate into multiple parallel substudies to 
include standardised trial operational structures, patient 
recruitment and selection, data collection, analysis, and 
management.18,75,76 In LMICs, adopting the framework of 
master protocols could be one way forward towards 
improving the coordination and sustainability of clinical 
research efforts in the global health field.
Clinical trial research in global health can often be 
fragmented and uncoordinated with a preponderance of 
short-term two-arm trials that have low statistical power 
and are small in scale. This preponderance of two-arm 
trials that have low statistical power can be attributed to a 
scarce funding availability, in which investigators 
compete for a small pool of funds. Funders rarely 
collaborate, and there might be little incentive for greater 
collaborations of researchers in geographical regions 
beyond their existing professional networks. This norm 
of short-term funding gives little room to consider 
building local infrastructure and human expertise. When 
these short-term trials finish, the infrastructure often 
disappears along with the data generated from research 
and the investigators who brought the funds from HICs, 
and investigators based in the country and who actively 
participated in the research are frequently omitted in 
peer-reviewed publications.28,77–79
To build a lasting research capacity in LMICs in a 
sustainable manner, equitable collaboration with the 
local researchers is needed. This collaboration, of course, 
should include fair equitable representation of local 
researchers from peer-reviewed publications and fair 
allocation of funds with local institutions. Collaboration 
between existing or newly established clinical trial 
networks (eg, AIDS Clinical Trials Group and European 
and Developing Countries Clinical Trials Partnership) 
should also be fostered and incentivised to allow for the 
exchange of ideas, supervision, and mentorship between 
different places, markets, or people that can facilitate the 
securing of resources and training, as well as educational 
opportunities in innovative trials designs, to ensure that 
efficient clinical trial research can be undertaken in a 
sustainable manner for global health.80–82
For example, maternal, newborn, and child health is 
one area in the field of global health that has seen 
fragmented and uncoordinated efforts, despite having 
clear and specific global targets set of reducing low 
birthweight by 30% and stunting in children younger 
than 5 years by 40% globally.83–85 The clinical trial evidence 
remains weak for interventions aimed at reducing 
adverse birth outcomes and child stunting in the first 
1000 days of life.86–88
A 2019 systematic review identified 169 RCTs in LMICs 
(comprising 302 061 participants) that evaluated the 
comparative efficacy of interventions under multiple 
domains of micronutrient and balanced energy protein 
or food supplements, deworming, maternal education, 
water sanitation, and hygiene during preg nancy, 
exclusive breastfeeding, and complementary feeding 
periods (ie, the first 1000 days of life; appendix p 2).89 For 
this key global health priority, 86 (51%) of 169 of these 
trials were of 26 weeks in duration or shorter, 69 (41%) of 
169 of the trials recruited fewer than 500 patients, and 
101 (60%) of 169 of the trials were not statistically 
conclusive on important clinical outcomes.89
Most of these trials were either single-centre trials 
or the trials had recruited patients from a few centres 
in the same country or region, usually around the 
capital city or a nearby region. Because clinical trials 
are often undertaken to estimate the population-level 
effects of given interventions, the norm of carrying out 
single-centre trials can be problematic for global health 
research. Geographical variation cannot be shown when 
trials are undertaken in a small number of centres and 
random effects of interventions arising from geographical 
variability cannot be estimated (appendix pp 3–4). If the 
intervention being investigated truly has no effects at the 
population level (null effects), the intervention might still 
show positive treatment effects if the trial is undertaken 
at one centre by play of chance. Trials carried out in this 
way would result in an inflated type I error rate because, 
in these single-centre trials, other locations that would 
show negative effects (which would cancel out the 
positive effect from the one centre with this finding) are 
omitted. Conversely, if the intervention does have a true 
positive treatment effect at the population level, an 
opposite effect (ie, failing to show an effect for an effective 
treatment) might be observed due to the use of a location 
that shows null or negative effect by chance. Thus, 
undertaking single-centre trials might result in a lower 
statistical power than multicentre trials.
All of these trials used fixed trial designs, even though 
well planned interim evaluations could have ended 
See Online for appendix
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the trials for reasons of superiority or futility and 
saved resources for other research. Interim analyses 
can also help protect participants. Early stopping 
for superiority could translate to early dissemination of 
effective interventions, and early stopping for futility 
could minimise unnecessary exposure to participants. 
The current evidence would arguably be stronger if the 
resources that were invested towards these multiple 
small two-arm clinical trials had been diverted into a few 
larger multi-arm trials with adequate statistical power 
and trial planning. Combined resources could also have 
allowed for the collection of biological samples 
and sociocultural data to better characterise the study 
context and, thus, allow for an improved understanding 
of the mechanism of interventions.29 We continue the 
discussions for interim analyses for early stopping and 
the framework of master protocols for global health in 
further detail in the second44 paper of this Series.
Conclusion
Clinical trial research has had a strong connection to 
global health that aims to improve health equities for 
populations that have a high burden of disease. Clinical 
trial research has identified many essential interventions 
for com municable diseases in LMICs but, with many 
LMICs rapidly transitioning into an NCD era, and with 
shortages of necessary funding for research, serious 
challenges await. The global health trial landscape 
has remained largely static over the past 70 years, with 
few examples of new methodological innovations being 
adopted. In the second paper of this Series, we outline 
new methods and tools that can be used to improve the 
efficiency and quality of global health clinical trials.
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